United States Breaking News

Eton Pharmaceuticals (NASDAQ:ETON) announced exclusive U.S. licensing and supply agreements with Aquestive Therapeutics (NASDAQ:AQST) for LIBERVANT, a seizure-cluster treatment.

Sono-Tek (NASDAQ:SOTK) reported fiscal first-half 2027 financial results, with revenue increasing 6% year over year to $10.893 million.

Bank of America's stock and fixed-income traders missed estimates in the third quarter, with bond-trading revenue falling 17% to $2.55 billion and equity trading down 10% to $2.51 billion. The bank's results were also hurt by a charge tied to a regulatory penalty over money laundering and sanctions violations. Kristine Aquino reports on Bloomberg Television.

Fastenal (NASDAQ:FAST) reported third-quarter 2026 financial results, delivering higher-than-expected revenue and earnings.

Bank of America (NYSE:BAC) reported third-quarter 2026 financial results with adjusted earnings per share of $1.08, compared with analyst expectations of $1.10.

Federal Reserve Vice Chair for Supervision Michelle Bowman said that although inflation remains above the central bank's goal, "I think we have some time to wait and see how financial conditions and the economy evolves." She spoke Wednesday with Institute of International Finance CEO Tim Adams at the IIF Annual Membership Meeting in Bangkok.

National Fuel Gas (NYSE:NFG) announced that its board of directors approved a plan to spin off its Integrated Upstream and Gathering (IUG) business into a separate public company.

Kamal Quadir, the Founder & CEO of bKash, a mobile financial service provider in Bangladesh, says that approval to operate as a digital bank will ease the access to capital for the customers. He spoke to Yvonne Man at Bloomberg's New Economic Forum on AI, banking and more.

Quoin Pharmaceuticals (NASDAQ:QNRX) announced that the European Medicines Agency has granted orphan drug designation to QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disorder.

Ocugen (NASDAQ:OCGN) entered an agreement granting Roots Pharmaceutical exclusive regional rights to OCU400, an investigational gene therapy for retinitis pigmentosa, an inherited vision-loss disease.

BlackRock (NYSE:BLK) reported third-quarter 2026 financial results with revenue of $7.8 billion, representing a 19% increase compared with the same period last year.

Verastem Oncology (NASDAQ:VSTM) reported updated Phase 1/2 TARGET-D 101 trial results for VS-7375, an investigational oral KRAS G12D inhibitor, across multiple KRAS G12D-mutated solid tumors.